BR9807234B1 - Composição farmacêutica compreendendo um composto tricílico e uma combinação de miristrato de isopropila e sebacato de dietila, com estabilidade e absorbilidade aumentadas e um pontencial de irritação reduzido - Google Patents
Composição farmacêutica compreendendo um composto tricílico e uma combinação de miristrato de isopropila e sebacato de dietila, com estabilidade e absorbilidade aumentadas e um pontencial de irritação reduzidoInfo
- Publication number
- BR9807234B1 BR9807234B1 BRPI9807234-0B1A BR9807234A BR9807234B1 BR 9807234 B1 BR9807234 B1 BR 9807234B1 BR 9807234 A BR9807234 A BR 9807234A BR 9807234 B1 BR9807234 B1 BR 9807234B1
- Authority
- BR
- Brazil
- Prior art keywords
- tricyl
- isopropil
- absorbility
- irritation
- compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Ophthalmology & Optometry (AREA)
- Reproductive Health (AREA)
- Transplantation (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Tropical Medicine & Parasitology (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP3617297 | 1997-02-20 | ||
JP25635797 | 1997-09-22 | ||
PCT/JP1998/000665 WO1998036747A1 (en) | 1997-02-20 | 1998-02-18 | Pharmaceutical composition |
Publications (2)
Publication Number | Publication Date |
---|---|
BR9807234A BR9807234A (pt) | 2000-04-25 |
BR9807234B1 true BR9807234B1 (pt) | 2013-11-05 |
Family
ID=26375217
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI9807234-0B1A BR9807234B1 (pt) | 1997-02-20 | 1998-02-18 | Composição farmacêutica compreendendo um composto tricílico e uma combinação de miristrato de isopropila e sebacato de dietila, com estabilidade e absorbilidade aumentadas e um pontencial de irritação reduzido |
Country Status (21)
Country | Link |
---|---|
US (1) | US6387918B1 (pt) |
EP (1) | EP0977565B1 (pt) |
JP (1) | JP3396888B2 (pt) |
KR (1) | KR100490357B1 (pt) |
CN (1) | CN1178656C (pt) |
AR (1) | AR011846A1 (pt) |
AT (1) | ATE237325T1 (pt) |
AU (1) | AU727337B2 (pt) |
BR (1) | BR9807234B1 (pt) |
CA (1) | CA2282345C (pt) |
DE (1) | DE69813542T2 (pt) |
DK (1) | DK0977565T3 (pt) |
EA (1) | EA003580B1 (pt) |
ES (1) | ES2193515T3 (pt) |
HK (1) | HK1027957A1 (pt) |
HU (1) | HU226163B1 (pt) |
IL (1) | IL131298A (pt) |
NO (1) | NO325103B1 (pt) |
PT (1) | PT977565E (pt) |
TW (1) | TW450810B (pt) |
WO (1) | WO1998036747A1 (pt) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2284248T3 (es) * | 1998-04-27 | 2007-11-01 | Astellas Pharma Inc. | Formulacion farmaceutica en gel que comprende un compuesto triciclico (fk-506/tacrolimus). |
GB9817064D0 (en) * | 1998-08-05 | 1998-10-07 | Fujisawa Pharmaceutical Co | New use |
US7063857B1 (en) | 1999-04-30 | 2006-06-20 | Sucampo Ag | Use of macrolide compounds for the treatment of dry eye |
US20030018044A1 (en) * | 2000-02-18 | 2003-01-23 | Peyman Gholam A. | Treatment of ocular disease |
AUPR529701A0 (en) * | 2001-05-28 | 2001-06-21 | Fujisawa Pharmaceutical Co., Ltd. | Pharmaceutical composition |
CN100473384C (zh) | 2001-11-29 | 2009-04-01 | 3M创新有限公司 | 包括免疫反应改性剂的药物制剂 |
EP2514420B1 (en) * | 2002-09-18 | 2014-08-13 | Trustees Of The University Of Pennsylvania | Use of rapamycin for the treatment or prevention of age-related macular degeneration |
ATE473003T1 (de) | 2003-08-29 | 2010-07-15 | Lifecycle Pharma As | Tacrolimus enthaltende feste dispersionen |
PT1663216E (pt) | 2003-08-29 | 2012-02-14 | Veloxis Pharmaceuticals As | Dispersões sólidas que compreendem tacrolímus |
US7585517B2 (en) * | 2003-09-18 | 2009-09-08 | Macusight, Inc. | Transscleral delivery |
US8663639B2 (en) * | 2005-02-09 | 2014-03-04 | Santen Pharmaceutical Co., Ltd. | Formulations for treating ocular diseases and conditions |
DK1848431T3 (en) * | 2005-02-09 | 2016-04-18 | Santen Pharmaceutical Co Ltd | LIQUID FORMULATIONS FOR TREATMENT OF DISEASES OR CONDITIONS |
JP5528708B2 (ja) | 2006-02-09 | 2014-06-25 | 参天製薬株式会社 | 安定な製剤ならびにそれらを調製および使用する方法 |
US7672006B2 (en) * | 2006-02-22 | 2010-03-02 | Xerox Corporation | Multi-marking engine printing platform |
CN103127100A (zh) | 2006-03-23 | 2013-06-05 | 参天制药株式会社 | 用于与血管通透性有关的疾病或病症的制剂和方法 |
WO2007120592A1 (en) * | 2006-04-10 | 2007-10-25 | Merck & Co., Inc. | Cgrp antagonist salt |
US20080265343A1 (en) * | 2007-04-26 | 2008-10-30 | International Business Machines Corporation | Field effect transistor with inverted t shaped gate electrode and methods for fabrication thereof |
PL2167033T4 (pl) | 2007-05-30 | 2018-08-31 | Veloxis Pharmaceuticals A/S | Podawana raz dziennie doustna postać dawkowania zawierająca takrolimus |
CN102176913B (zh) * | 2008-10-08 | 2014-08-13 | 高田制药株式会社 | 外用的他克莫司制剂 |
ES2591352T3 (es) | 2010-02-17 | 2016-11-28 | Veloxis Pharmaceuticals A/S | Composición de tacrolimus estabilizada |
JP5674786B2 (ja) * | 2010-07-23 | 2015-02-25 | マルホ株式会社 | タクロリムスを含有する水中油型クリーム状組成物 |
WO2012011192A1 (ja) * | 2010-07-23 | 2012-01-26 | マルホ株式会社 | タクロリムスを含有する水中油型クリーム状組成物 |
KR101890011B1 (ko) * | 2011-12-07 | 2018-08-20 | 히사미쓰 세이야꾸 가부시키가이샤 | 첩부제 |
WO2013111817A1 (ja) * | 2012-01-25 | 2013-08-01 | マルホ株式会社 | タクロリムスを含有する水中油型クリーム状組成物 |
US20180243224A1 (en) | 2015-08-19 | 2018-08-30 | Vivus, Inc. | Pharmaceutical formulations |
CN110785161B (zh) | 2017-06-23 | 2023-06-20 | 宝洁公司 | 用于改善皮肤外观的组合物和方法 |
WO2019233722A1 (en) | 2018-06-08 | 2019-12-12 | Almirall, S.A. | Pharmaceutical composition comprising tacrolimus |
CA3102288A1 (en) | 2018-07-03 | 2020-01-09 | The Procter & Gamble Company | Method of treating a skin condition |
JP2023528616A (ja) | 2020-06-01 | 2023-07-05 | ザ プロクター アンド ギャンブル カンパニー | ビタミンb3化合物の皮膚への浸透を改善する方法 |
US10959933B1 (en) | 2020-06-01 | 2021-03-30 | The Procter & Gamble Company | Low pH skin care composition and methods of using the same |
AU2022230995A1 (en) | 2021-03-03 | 2023-09-14 | Sana Biotechnology, Inc. | Immunosuppressive therapies for use with cardiomyocyte cell therapies, and associated methods and compositions |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0406791B1 (en) * | 1989-07-05 | 1995-02-01 | Fujisawa Pharmaceutical Co., Ltd. | Aqueous liquid composition for external use |
ES2099112T3 (es) * | 1990-09-04 | 1997-05-16 | Fujisawa Pharmaceutical Co | Pomadas que contienen un compuesto triciclico. |
CA2054983A1 (en) * | 1990-11-08 | 1992-05-09 | Sotoo Asakura | Suspendible composition and process for preparing the same |
JPH06183970A (ja) | 1992-12-16 | 1994-07-05 | Fujisawa Pharmaceut Co Ltd | 医薬用組成物 |
JPH06345646A (ja) * | 1993-06-08 | 1994-12-20 | Fujisawa Pharmaceut Co Ltd | ローション剤 |
BR9509530A (pt) * | 1994-10-26 | 1997-10-14 | Novartis Ag | Composições farmacêuticas |
-
1998
- 1998-02-17 TW TW087102169A patent/TW450810B/zh not_active IP Right Cessation
- 1998-02-18 EP EP98904366A patent/EP0977565B1/en not_active Expired - Lifetime
- 1998-02-18 IL IL13129898A patent/IL131298A/en not_active IP Right Cessation
- 1998-02-18 CN CNB988043440A patent/CN1178656C/zh not_active Expired - Fee Related
- 1998-02-18 AT AT98904366T patent/ATE237325T1/de active
- 1998-02-18 ES ES98904366T patent/ES2193515T3/es not_active Expired - Lifetime
- 1998-02-18 PT PT98904366T patent/PT977565E/pt unknown
- 1998-02-18 US US09/367,698 patent/US6387918B1/en not_active Expired - Lifetime
- 1998-02-18 AU AU62289/98A patent/AU727337B2/en not_active Ceased
- 1998-02-18 KR KR10-1999-7007087A patent/KR100490357B1/ko not_active IP Right Cessation
- 1998-02-18 HU HU0000979A patent/HU226163B1/hu not_active IP Right Cessation
- 1998-02-18 DE DE69813542T patent/DE69813542T2/de not_active Expired - Lifetime
- 1998-02-18 JP JP53648298A patent/JP3396888B2/ja not_active Expired - Lifetime
- 1998-02-18 EA EA199900749A patent/EA003580B1/ru not_active IP Right Cessation
- 1998-02-18 BR BRPI9807234-0B1A patent/BR9807234B1/pt not_active IP Right Cessation
- 1998-02-18 DK DK98904366T patent/DK0977565T3/da active
- 1998-02-18 CA CA002282345A patent/CA2282345C/en not_active Expired - Fee Related
- 1998-02-18 WO PCT/JP1998/000665 patent/WO1998036747A1/en active IP Right Grant
- 1998-02-20 AR ARP980100785A patent/AR011846A1/es active IP Right Grant
-
1999
- 1999-08-19 NO NO19994003A patent/NO325103B1/no not_active IP Right Cessation
-
2000
- 2000-10-31 HK HK00106933A patent/HK1027957A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR9807234B1 (pt) | Composição farmacêutica compreendendo um composto tricílico e uma combinação de miristrato de isopropila e sebacato de dietila, com estabilidade e absorbilidade aumentadas e um pontencial de irritação reduzido | |
KR970006279A (ko) | 약제학적 활성 성분으로서의 6-디메틸아미노메틸-1-페닐-사이클로헥산 화합물 | |
FI973828A (fi) | Yhdisteitä ja koostumuksia aktiivisten aineiden annostelemiseksi | |
ID18663A (id) | Komposisi farmasi berlapis enterik | |
DE69634053D1 (de) | Oral anzuwendende Arzneizusammensetzung enthaltend 2-Methyl-thienobenzodiazepin | |
NO20004345D0 (no) | Farmasøytisk sammensetning | |
FI955144A0 (fi) | Päällystetyt farmaseuttiset koostumukset | |
HUP9601566A3 (en) | Therapeutic tetrahydro-isoquinolin derivatives, their intermediates and pharmaceutical compositions containing the active component | |
EE9700241A (et) | Farmatseutiline kompositsioon transdermaalseks manustamiseks | |
BR9609738A (pt) | Composições para aplicação de droga para estabilidade melhorada de esteróides | |
PT1066027E (pt) | Composicao farmaceutica de topiramato | |
FI972292A0 (fi) | Administrering av diabetes | |
ID22973A (id) | Komposisi farmasi dari pemberian oral dari turunan n-piperidino-3-pirazolkarboksamida, garam-garam dan solvatnya | |
IS4706A (is) | Lyfjasamsetningar | |
PT907364E (pt) | Composicao farmaceutica de libertacao sustida | |
PT946185E (pt) | Composicao farmaceutica compreendendo um composto que possui actividade anti-xa e um composto antagonista da agregacao plaquetaria | |
EE200000226A (et) | 3,6-poolketaalid 9a-asaliidide klassist, nende valmistamismeetod ja farmatseutiline kompositsioon | |
FI973229A0 (fi) | Uusi farmaseuttinen koostumus | |
LV11727A (lv) | Farmaceitiska kompozicija | |
ID29294A (id) | Komposisi farmasi | |
MA26531A1 (fr) | Composition pharmaceutique | |
ID25857A (id) | Komposisi farmasi | |
FI973280A (fi) | Farmaseuttinen koostumus | |
EE04347B1 (et) | 8-asabitsüklo[3.2.1]oktaan-3-metaanamiini derivaadid, neid sisaldav ravim ja farmatseutiline kompositsioon | |
BR9605777A (pt) | Composição farmacêutica |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25A | Requested transfer of rights approved |
Owner name: YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) Free format text: TRANSFERIDO POR FUSAO DE: FUJISAWA PHARMACEUTICAL CO., LTD. |
|
B25D | Requested change of name of applicant approved |
Owner name: ASTELLAS PHARMA INC. (JP) Free format text: ALTERADO DE: YAMANOUCHI PHARMACEUTICAL CO., LTD. |
|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: INDEFIRO O PRESENTE PEDIDO DE ACORDO COM ARTIGO 37, E COM BASE NOS ARTIGOS 8O, 13 E 25 DA LPI |
|
B12B | Appeal against refusal [chapter 12.2 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 05/11/2013, OBSERVADAS AS CONDICOES LEGAIS. |
|
B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 19A ANUIDADE. |
|
B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |